Syndax Pharmaceuticals Inc To Host Axatilimab AGAVE-201 Topline Data Call Transcript
Good day, everyone, and welcome to the Pivotal AGAVE-201 Top Line Axatilimab Data Conference Call. Today's call is being recorded.
At this time, I would like to turn the call over to Sharon Klahre, Head of Investor Relations at Syndax Pharmaceuticals.
Thank you, operator. Welcome, and thank you all for joining us today. I'm Sharon Klahre, and with me this morning to provide a review of top line results from the pivotal AGAVE-201 of axatilimab in adult and pediatric patients with chronic graft-versus-host disease, following two or more prior lines of therapy, are Michael Metzger, Chief Executive Officer; and Dr. Niel Gallagher, President and Head of R&D. Also joining us on the call today for the question-and-answer session are Dr. Peter Ordentlich, Chief Scientific Officer; Dr. Anjali Ganguli; Chief Business Officer; and Keith Goldan, Chief Financial Officer.
This morning, we issued a joint press release with Incyte, reporting top line data for the pivotal AGAVE
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |